KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Travere Therapeutics (TVTX) Gross Margin (2016 - 2025)

Travere Therapeutics' Gross Margin history spans 12 years, with the latest figure at 98.03% for Q4 2025.

  • For Q4 2025, Gross Margin rose 145.0% year-over-year to 98.03%; the TTM value through Dec 2025 reached 97.17%, up 50.0%, while the annual FY2025 figure was 97.89%, 121.0% up from the prior year.
  • Gross Margin reached 98.03% in Q4 2025 per TVTX's latest filing, up from 96.04% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 98.67% in Q2 2025 to a low of 86.58% in Q1 2023.
  • Average Gross Margin over 5 years is 95.23%, with a median of 96.36% recorded in 2024.
  • Peak YoY movement for Gross Margin: crashed -717bps in 2023, then skyrocketed 978bps in 2024.
  • A 5-year view of Gross Margin shows it stood at 97.11% in 2021, then dropped by 0bps to 97.04% in 2022, then decreased by -7bps to 89.87% in 2023, then rose by 7bps to 96.59% in 2024, then grew by 1bps to 98.03% in 2025.
  • Per Business Quant, the three most recent readings for TVTX's Gross Margin are 98.03% (Q4 2025), 96.04% (Q3 2025), and 98.67% (Q2 2025).